NewsBenzingaRBC Capital mantiene su recomendación de sobreponderar sobre Design Therapeutics y reduce su precio objetivo a 19 dólares. RBC Capital mantiene su recomendación de sobreponderar sobre Design Therapeutics y reduce su precio objetivo a 19 dólares. Benzinga 2026.11.05 18:56 (GMT+0) Open on Benzinga Other news What Are Wall Street Analysts' Target Price for Lumentum Holdings Stock? Texas Pacific Land Stock: Analyst Estimates & Ratings Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday